MONSEY, N.Y., Feb. 07, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating whether Catalent, Inc. (NYSE:CTLT) ("Catalent") has violated federal securities laws based on a report by Bloomberg alleging that inspectors from the U.S. Food and Drug Administration ("FDA") found that safety and quality standards are not being met at an Indiana factory operated by Catalent that manufactures the popular weight injection Wegovy. The plant is among those being acquired by Novo Nordisk in connection with the recently announced acquisition of Catalent by Novo Holdings.
If you have questions about your legal rights in light of the above news, please contact us at the following link to discuss your options at no charge:
https://wohlfruchter.com/cases/catalent/
Alternatively, you ...